Drug Information Rounds

Beckett BE . Headache disorders. In: DiPiro J Talbert R Yee G Matzke G Wells B Posey L , eds. Pharmacotherapy: A pathophysiologic approach. 3rd ed. Stamford, CT: Appleton & Lange, 1996; 1279–91.

McKenna J . Cluster headaches. Am Fam Physician 1988; 37:173–8.

Maizels M Scott B Cohen W Chen W . Intranasal lidocaine for treatment of migraine. JAMA 1996; 276:319–21.

International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; (suppl 7): 1–96.

Diamond S . The management of migraine and cluster headaches. Compr Ther 1995; 21:492–8.

Goadsby PJ Edvinsson L . The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33:48–56.

Moskowitz M . The neurobiology of vascular head pain. Ann Neurol 1984; 16:157–68.

Sluder G . The role of the sphenopalatine ganglion in nasal headaches. N Y State J Med 1908; 27:8–13.

Goadsby PJ Lambert GA Lance JW . The peripheral pathway for extracranial vasodilatation in the cat. J Auton Nerv Syst 1984; 10:145–55.

Kittrelle J Grouse D Seybold M . Cluster headache: Local anesthetic abortive agents. Arch Neurol 1985; 42:496–8.

Kudrow L Kudrow D Sandweiss JH . Rapid and sustained relief of migraine attacks with intra-nasal lidocaine. Headache 1995; 35:79–82.

Barré F . Cocaine as an abortive agent in cluster headache. Headache 1982; 22:69–73.

Vail HH . Vidian neuralgia. Ann Otol Rhinol Laryngol 1932; 41:837–56.

Vail HH . Vidian neuralgia from disease of sphenoidal sinus; report of a case. Arch Surg 1929; 18:1247–55.

Robbins L . Intranasal lidocaine for cluster headache. Headache 1995; 35:83–4.

Hargrove JT Eisenberg E . Menopause. Med Clin North Am 1995; 79:1337–56.

Cobleigh MA Berris RF Bush T Davidson NE Robert NJ Sparano JA . Estrogen replacement therapy in breast cancer survivors: A time for change. JAMA 1994; 272:540–5.

Ginsburg ES . Hot flashes — Physiology, hormonal therapy, and alternative therapies. Obstet Gynecol Clin North Am 1994; 21:381–90.

Miller KL . Alternatives to estrogen for menopausal symptoms. Clin Obstet Gynecol 1992; 35:884–93.

Loprinzi CL Michalak JC Quella SK O'Fallon JR Hatfield AK Nelimark RA , Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331:347–52.

Young RL Kumar NS Goldzieher JW . Management for menopause when estrogen cannot be used. Drugs 1990; 40:200–30.

Schiff I Tulchinsky D Cramer D Ryan K . Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA 1980; 244:1443–5.

Albrecht BH Schiff I Tulchinsky D Ryan KJ . Objective evidence that placebo and oral medroxyprogesterone acetate therapy diminish menopausal vasomotor flushes. Am J Obstet Gynecol 1981; 139:631–5.

Laufer LR Erlik Y Meldrum DR Judd HL . Effect of clonidine on hot flashes in postmenopausal women. Obstet Gynecol 1982; 60:583–6.

Wren BG Brown LB . A double-blind trial with clonidine and a placebo to treat hot flushes. Med J Aust 1986; 144:369–70.

Goldberg RM Loprinzi CL O'Fallon JR Veeder MH Miser AW Mailliard JA , Transdermal clonidine for ameliorating tamoxifen induced hot flashes. J Clin Oncol 1994; 12:155–8.

Kronenberg F . Hot flashes: Phenomenology, quality of life and search for treatment options. Exp Gerontol 1994; 29:319–36.

Shaver JLF . Beyond hormonal therapies in menopause. Exp Gerontol 1994; 29:469–76.

Garfinkel BD Wender PH . Attention-deficit hyperactivity disorder. In: Kaplan HI Sadock BJ , eds. Comprehensive textbook of psychiatry. 5th ed. Baltimore: Williams and Wilkins, 1989; 1828–37.

Selikowitz M . All about A.D.D.: Understanding attention deficit disorder. Melbourne: Oxford University Press, 1995.

Barkley RA . Taking charge of ADHD: The complete authoritative guide for parents. New York: The Guilford Press, 1995.

Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994:78–85.

Scahill L French PT . Nonstimulant medications in the treatment of attention deficit hyperactivity disorder. J Child Adolesc Psychiatr Nurs 1996; 9:39–43.

Spencer T Biederman J Wilens T Harding M O'Donnell D Griffin S . Pharmacotherapy of attention-deficit hyperactivity across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35:409–32.

Biederman J Gastfriend DR Jellinek MS . Desipramine in the treatment of attention-deficit hyperactivity disorder. J Clin Psychopharmacol 1986; 6:359–62.

Wilens TE Biederman J Baldessarini RJ Geller B Schleifer D Spencer TJ , Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 1996; 35:1491–501.

Spencer T Biederman J Wilens T Steingard R Geist D . Nortriptyline treatment of children with attention-deficit hyperactivity disorder and tic disorder of Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1993; 32:205–10.

Hunt RD Minderaa RB Cohen DJ . Clonidine benefits children with attention deficit disorder and hyperactivity: Report of a double-blind, placebo-crossover therapeutic trial. J Am Acad Child Psychiatry 1985; 24:617–29.

Chappel PB Riddle MA Scahill L Lynch KA Schultz R Arnsten A , Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: Preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995; 34:1140–6.

Hunt RD Arnsten AF Asbell MD . An open trial of guanfacine in the treatment of attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995; 34:50–4.

Hinshaw SP . Behavioral rating scales in the assessment of disruptive behavioral disorders in children. In: Shaffer D Richters J , eds. Assessment in child psychopathology. New York: Cambridge Press, 1994.

Kelly CP Pothoulakis C LaMont JT . Clostridium difficile colitis. N Engl J Med 1994; 330:257–62.

Bartlett JG . Clostridium difficile: Clinical considerations. Rev Infect Dis 1990; 12(suppl 2):S243–51.

Fekety R Shah AB . Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993; 269:71–5.

McFarland LV Mulligan ME Kwok RYY Stamm WE . Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320:204–10.

Stergachis A Perera DR Schnell MM Jick H . Antibiotic-associated colitis. West J Med 1984; 140:217–9.

Reinke CM Messick CR . Update on Clostridium difficile-induced colitis, part 1. Am J Hosp Pharm 1994; 51:1771–81.

McFarland LV Surawicz CM Stamm WE . Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 1990; 162:678–84.

Danziger LH Itokazu GS . Gastrointestinal infections. In: Young LE Koda-Kimble MA , eds. Applied therapeutics: The clinical use of drugs. 6th ed. Vancouver, WA: Applied Therapeutics, Inc., 1995: 60, 10–12.

Teasley DG Gerding DN Olson MM Peterson LR Gebhard RL Schwartz MJ . Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983; 2:1043–6.

Bolton RP Culshaw MA . Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27:1169–72.

Fekety R Silva R Kauffman C Buggy B Deery HG . Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: Comparison of two dosage regimens. Am J Med 1989; 86:15–9.

Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995; 16:105–13.

Bartlett JG Tedesco FJ Shull S Lowe B Chang T . Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology 1980; 78:431–4.

Surawicz CM McFarland LV Elmer G Chinn J . Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastrenterol 1989; 84:1285–7.

McFarland LV Surawicz CM Greenberg RN Fekety R Elmer GW Moyer KA . A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271:1913–8.

Kimmey MB Elmer GW Surawicz CM McFarland LV . Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii. Dig Dis Sci 1990; 35:897–901.

Hassett J Meyers S McFarland L Mulligan ME . Recurrent Clostridium difficile infection in a patient with selective IgG1 deficiency treated with intravenous immune globulin and Saccharomyces boulardii. Clin Infect Dis 1995; 20(suppl 2):S266–8.

Buts JP Corthier G Delmee M . Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. J Pediatr Gastroenterol Nutr 1993; 16:419–25.

Elmer GW Surawicz CM McFarland LV . Biotherapeutic agents: A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 1996; 275:870–6.

Fekety R Shah AB . Diagnosis and treatment of Clostridium difficile colitis. JAMA 1993; 269:71–5.

Pothoulakis C Kelly CP Joshi MA Gao N O'Keane CJ Castagliuolo I . Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993; 104:1108–15.

Buts JP Bernasconi P Vaerman JP Dive C . Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 1990; 35:251–6.

Caetano JAM Parames MT Babo MJ Santos A Ferreira A Bandeira Freitas AA . Immunopharmacologic effects of Saccharomyces boulardii in healthy human volunteers. Int J Immunopharmacol 1986; 8:245–59.

Blehaut H Massot J Elmer GW Levy RH . Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Dispos 1989; 10:353–64.

Plentincx M Legein J Vandenplas Y . Fungemia with Saccharomyces boulardii in a 1-year-old girl with protracted diarrhea. J Pediatr Gastroenterol Nutr 1995; 21:113–5.